Hemophilia A Treatment Market Size In 7MM Is Expected To Grow At A Decent CAGR By 2034, Estimates Delveinsight

DelveInsight's“ Hemophilia A Market Insights, Epidemiology, and Market Forecast – 2034 ” report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Discover which therapies are expected to grab the Hemophilia A Market Share @ Hemophilia A Market Outlook Key Takeaways from the Hemophilia A Market Report Stay ahead in the Hemophilia A Therapeutics Market with DelveInsight's Strategic Report @ Hemophilia A Market Outlook Hemophilia A Epidemiology Segmentation in the 7MM Download the report to understand which factors are driving Hemophilia A Epidemiology trends @ Hemophilia A Prevalence Marketed Hemophilia A Drugs ROCTAVIAN (valoctocogene roxaparvovec) is an AAV5 gene therapy for treating severe hemophilia A. It delivers a functional gene designed to enable the body to produce Factor VIII independently without needing continued hemophilia prophylaxis, thus relieving patients of their treatment burden relative to currently available therapies.

People with hemophilia A have a mutation in the gene responsible for producing Factor VIII, a protein necessary for blood clotting. The expressed hFVIII-SQ replaces the missing coagulation factor VIII needed for effective hemostasis. Following valoctocogene roxaparvovec infusion, vector DNA is processed in vivo to form full-length, episomal transgenes that persist as the stable DNA forms that support the long-term production of hFVIII-SQ.



OBIZUR treats bleeding episodes in adults with acquired hemophilia (a bleeding disorder caused by a lack of Factor VIII activity due to antibody development). These antibodies have a less neutralizing effect against OBIZUR than against human Factor VIII. OBIZUR contains the active substance susoctocog alfa, antihemophilic Factor VIII, and porcine sequence.

Emerging Hemophilia A Drugs Fitusiran, currently under development by Sanofi (Genzyme)/Alnylam Pharmaceuticals, is a subcutaneously administered small interfering RNA (siRNA) technology to target antithrombin. In Q2 2022, the company announced data with lower doses expected in the second half of 2023. The company anticipates the first filing by 2024.

The Pediatric (age 1–11) study is ongoing, and the company expects the first filing by 2026. Marstacimab, which is currently under development by Pfizer, is a Tissue Factor Pathway Inhibitor monoclonal antibody to treat Hemophilia A and B with or without Inhibitors. Currently, it is in Phase III clinical trial for the treatment of severe Hemophilia A and B with or without Inhibitors.

The company also projected a pivotal readout in Q2 2023 and projected submission for non-inhibitor indication in Q3 2023. To learn more about Hemophilia A treatment guidelines, visit @ Hemophilia A Treatment Market Landscape Hemophilia A Drugs Market Insights In the Hemophilia A market, there are several third-generation products available; ADVATE (Baxter) and XYNTHA (Pfizer) are examples of recombinant factor VIII products. There are several other products approved under this category; however, these products were approved a long time ago, and since then, short and longer-acting recombinant (not derived from human plasma) factor therapies have entered the market, of which ELOCTATE and ADVATE have gained the popularity, in terms of treatment horizon of Hemophilia A.

ELOCTATE is a recombinant fusion protein that temporarily replaces the missing Coagulation Factor VIII needed for effective hemostasis. KOGENATE FS is a new formulation of recombinant factor VIII formulated with sucrose, as opposed to human plasma protein (Albumin). Another class of factor concentrate is plasma-derived factor concentrate FVIII products that are produced by utilizing human plasma.

Hemophilia A Market Outlook In the Hemophilia A Market, several recombinant factor VIII (FVIII) products are available with high-specific activities (the amount of desired clotting factor per mg of total protein). Plasma-derived clotting factors products are also available. However, the current market is mainly dominated by the recombinants of several generations (recombinant third-generation and recombinant second-generation).

Learn more about the FDA-approved drugs for Hemophilia A @ Drugs for Hemophilia A Treatment Scope of the Hemophilia A Market Report Table of Content 1. Key Insights 2. Hemophilia A Report Introduction 3.

Hemophilia A Market Overview at a Glance 4. Executive Summary of Hemophilia A 5. Key Events 6.

Hemophilia A SWOT Analysis 7. Hemophilia A Epidemiology and Market Methodology 8. Hemophilia A: Disease Background and Overview 9.

Hemophilia A Treatment Algorithm, Current Treatment, and Medical Practices 10. Hemophilia A Epidemiology and Patient Population 11. Patient Journey of Hemophilia A 12.

Key Endpoints in Hemophilia A Clinical Trials 13. Hemophilia A Marketed Drugs 14. Hemophilia A Emerging Drugs 15.

Hemophilia A: Seven Major Market Analysis 16. Hemophilia A Market Access and Reimbursement 17. Hemophilia A Unmet Needs 18.

Appendix 19. DelveInsight Capabilities 20. Disclaimer 21.

About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

MENAFN28032025003238003268ID1109369705 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

.